Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 1700 • ACR Convergence 2024
Comparative Effectiveness of Sarilumab vs. Methotrexate as a Glucocorticoid-Sparing Agent in Patients with Polymyalgia Rheumatica
Jeffrey Curtis¹, Fenglong Xie², Shanette Daigle³ and Sebastian E. Sattui⁴, ¹The University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³FASTER, Birmingham, AL, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory condition that typically affects older individuals for whom long term glucocorticoid (GC) use may be undesirable. Moreover, the…
Abstract Number: 0768 • ACR Convergence 2024
Addressing Gaps in Polymyalgia Rheumatica: A Systematic Literature Review
Shelley Fritz¹, Angela Degrassi², Kelly Gavigan², Ruohan Hong³, Santiago Munoz Perez², Esteban Rivera⁴, Erik Stone⁵, Laura Stradford⁶, Ambika Vartak², Anne Sydor² and Shilpa Venkatachalam³, ¹Global Healthy Living Foundation, Kalaheo, HI, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Long Island City, NY, ⁵Global Healthy Living Foundation, Upper Nyack, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: This systematic literature review on polymyalgia rheumatica (PMR) and PMR with giant cell arteritis (GCA) evaluates existing literature on disease burden, management, and treatment…
Abstract Number: 1704 • ACR Convergence 2024
Cluster Analysis of Peripheral Blood Mononuclear Cell Subpopulations Using Deep Immunophenotyping, Multiplex Serum Cytokines and Small Lipid Mediators at the Very Early Stages of Steroid Treatment in Polymyalgia Rheumatica and Giant Cell Arteritis
Dimitrios Anastasios Palamidas¹, Maria Papadaki², Nikolaos Paschalidis³, Eleftherios Pavlos⁴, Loukas chatzis¹, Ourania Argyropoulou⁵, Panagiota Palla⁵, Ioanna-Evdokia Galani⁶, Andreas Goules⁷, Evangelos Andreakos⁴ and Athanasios Tzioufas⁸, ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ²Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Attiki, Greece, ³Mass Cytometry-CyTOF Laboratory, Center for Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece, Cholargos Athens, Greece, ⁴Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Athens, Greece, ⁵Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁶Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Greece, ⁷GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁸LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are autoimmune/autoinflammatory disorders affecting patients over 50 years and are characterized by an acute inflammatory response.…
Abstract Number: 0769 • ACR Convergence 2024
Baseline Evaluation of Diagnoses and Prescribing Patterns in Polymyalgia Rheumatica
Laura Stradford¹, Shilpa Venkatachalam², Kelly Gavigan³, Angela Degrassi³, Emily Holladay⁴, Fenglong xie⁵, Yujie Su⁶, Shanette Daigle⁷ and Jeffrey Curtis⁸, ¹Global Healthy Living Foundation, Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁶Illumination Health, Hoover, AL, ⁷FASTER, Birmingham, AL, ⁸University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Polymyalgia rheumatica (PMR) is a chronic inflammatory rheumatic condition that affects approximately 800,000 people in the U.S., occurring almost exclusively after age 50. Moreover,…
Abstract Number: 1725 • ACR Convergence 2024
Exploring Risks of Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA) and Complications While Receiving Immune Checkpoint Inhibitors: Comparative Analysis
Irakli Tskhakaia and Arthur Lau, Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, offering significant benefits in various malignancies. However, these therapies can induce immune-related adverse events (irAEs), including…
Abstract Number: 0858 • ACR Convergence 2024
Baricitinib in Early Polymyalgia Rheumatica (BACHELOR Study)
Alain SARAUX¹, Guillermo CARVAJAL ALEGRIA², Emmanuelle Dernis³, christian roux⁴, Christophe Richez⁵, Alice TISON⁶, Baptiste Quere⁷, Sandrine Jousse-Joulin⁸, Dewi Guellec⁷, Thierry Marhadou⁹, Patrice Kervarrec⁷, Divi Cornec¹⁰, Catherine Le Henaff⁷, Sandra Lesven⁷, nowak emmanuel⁷, Aghiles Souki⁷ and Valerie Devauchelle¹¹, ¹CHU Brest, Brest, France, ²CHRU de Tours, Tours, France, ³CH LE MANS, LE MANS, Pays de la Loire, France, ⁴rheumatology department, university Cote d'Azur, nice, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶CHU de la Cavale Blanche, Brest, France, Brest, France, ⁷Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, ⁸cavale blanche hospital, brest, France, ⁹CHU Cavale Blanche, Brest, France, ¹⁰University of Brest, Brest, France, ¹¹UBO, Brest, France
Background/Purpose: Moderate glucocorticoids (GCs) improve nearly all cases of polymyalgia rheumatica (PMR) but related adverse events are common in senior patients. The purpose of this…
Abstract Number: 1974 • ACR Convergence 2024
The Impact of Concomitant Shoulder Osteoarthritis in Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², Robert Harrington³, David Kane⁴ and Richard Conway⁵, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³St. James's Hospital, Dublin, Dublin, Ireland, ⁴Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁵Trinity College Dublin, Dublin, Ireland
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease of the shoulder and pelvic girdle. In the majority of centres, baseline shoulder radiograph forms part…
Abstract Number: 0859 • ACR Convergence 2024
Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Kylie Carlson¹, Mahmut Kaymakci², Sebastian E. Sattui³ and Michael Putman⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Mayo Clinic, Rochester, MN, ³University of Pittsburgh, Pittsburgh, PA, ⁴The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Patients with polymyalgia rheumatica (PMR) may develop overt giant cell arteritis (GCA), but “subclinical” large vessel inflammation has also been reported in patients with…
Abstract Number: 1983 • ACR Convergence 2024
Immune Checkpoint Inhibitor Associated Vasculitis and Polymyalgia Rheumatica: A Systematic Review
Aaron Teel¹, Adrian Grebowicz², Mats Junek³, Stephanie Garner⁴, Tom Appleton⁵ and Faiza Khokhar⁶, ¹London Health Sciences Centre, Sarnia, ON, Canada, ²Western University, London, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵The University of Western Ontario, London, ON, Canada, ⁶McMaster University, St. Joseph's Hamilton, Mississauga, ON, Canada
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy that have been associated with immune-related adverse events (irAEs). These include multiple rheumatic diseases…
Abstract Number: 0881 • ACR Convergence 2024
Cytokine Profile of Newly Diagnosed Patients with Isolated Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², Robert Harrington³, David Kane⁴, Jean Dunne⁵, Niall conlon⁶ and Richard Conway⁷, ¹Trinity College Dublin, Dublin 8, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ³St. James's Hospital, Dublin, Dublin, Ireland, ⁴Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁵Trinity College Dublin, Dublin, ⁶Trinity Colleg Dublin, Dublin, ⁷Trinity College Dublin, Dublin, Ireland
Background/Purpose: Despite polymyalgia rheumatica (PMR) being the most common inflammatory rheumatic disease in those over the age of 50 years, there remains a significant unmet…
Abstract Number: 2150 • ACR Convergence 2024
Understanding Unmet Needs and Quality of Life Impact of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) Using Social Media: A Patient and Caregiver Perspective
Pallavi Arun¹, Nikita Parashar¹, Sakshi Sharma¹, Kanika Arora¹, Vandana Padmanabhan¹ and Alvaro Arjona², ¹Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ²Novartis Farmaceutica, S.A., Madrid, Madrid, Spain
Background/Purpose: Analyzing social media conversations of patients (pts) and caregivers can be useful to understand the real-world perspectives thereby improving quality of healthcare.1 GCA and…
Abstract Number: 0276 • ACR Convergence 2024
Exploring the Prevalence of Crowned Dens Syndrome in a Polymyalgia Rheumatica Veterans Affairs Patient Cohort
Marlene Marte Furment¹, Binod Kc¹, Bhavya Poudyal¹, Aakritee Sharma Subedi², Mahnoor Sherazi³, Jihad Ben Gabr¹, Shveta Trikha⁴, Brian Cooney⁵ and Fatme Allam⁵, ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY Upstate University Hospital, Syracuse, ³State University of New York, Syracuse, NY, ⁴Syracuse VA Medical Center, Syracuse, ⁵Syracuse VA Medical Center, Syracuse, NY
Background/Purpose: Crowned Dens (CD) is the radiological finding of calcium pyrophosphate dihydrate (CPPD) crystal deposition in the cruciform and alar ligaments giving the appearance of…
Abstract Number: 0975 • ACR Convergence 2024
Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica
Sebastian E. Sattui¹, FRANK HARTMUT DR. BUTTGEREIT², Merav Lidar³, Kerri Ford⁴, Stefano Fiore⁵, Lita Araujo⁴, Timothy Beukelman⁶, Fenglong Xie⁷ and Jeffrey Curtis⁸, ¹University of Pittsburgh, Pittsburgh, PA, ²Charité University Medicine Berlin, Berlin, Germany, ³Rheumatology Unit, Sheba Medical Center, Tel Hashomer, Israel, ⁴Sanofi, Cambridge, MA, ⁵Sanofi, Bridgewater, NJ, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: PMR, a common inflammatory rheumatic disease in older adults, is primarily treated with glucocorticoids (GC). A high comorbidity burden in PMR may increase the…
Abstract Number: 2508 • ACR Convergence 2024
The Impact of Lipid Profile Parameters on the Incidence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis Patients: A Single-arm Meta-Analysis
Nouman Shafique¹, Ali Raza Khan², Abdul Qadeer², zaigham Shaukat² and Rabia Iqbal², ¹AdventHealth Orlando, Orlando, FL, ²Nishtar Medical University, Multan, Punjab, Pakistan
Background/Purpose: Cardiovascular diseases (CVD) are a significant cause of morbidity and mortality among patients with rheumatoid arthritis (RA), accounting for nearly 40% of their mortality.…
Abstract Number: 1054 • ACR Convergence 2023
Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT
David Liew¹, Aurora Poon¹, Christopher McMaster², Russell Buchanan¹, Victor Yang¹, Andrew Scott¹ and Claire Owen³, ¹Austin Health, Heidelberg, Australia, ²Austin Health, Pascoe Vale South, Australia, ³Austin Health, Malvern East, Australia
Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].